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Abstract 
Loss of circadian rhythmicity fundamentally affects the neuroendocrine, immune and 
autonomic system, similar to chronic stress and may play a central role in the development of 
stress-related disorders. Recent articles have focused on the role of sleep and circadian 
disruption in the pathophysiology of posttraumatic stress disorder (PTSD), suggesting that 
chronodisruption plays a causal role in PTSD development. Direct and indirect human and 
animal PTSD research suggests circadian-system-linked neuroendocrine, immune, 
metabolic and autonomic dysregulation, linking circadian misalignment to PTSD 
pathophysiology. Recent experimental findings also support a specific role of the 
fundamental synchronizing pineal hormone melatonin in mechanisms of sleep, cognition and 
memory, metabolism, pain, neuroimmunomodulation, stress endocrinology and physiology, 
circadian gene expression, oxidative stress and epigenetics, all processes affected in PTSD. 
In the current paper, we review available literature underpinning a potentially beneficiary role 
of an add-on melatonergic treatment in PTSD pathophysiology and PTSD-related symptoms. 
The literature is presented as a narrative review, providing an overview on the most 
important and clinically relevant publications. We conclude that adjuvant melatonergic 
treatment could provide a potentially promising treatment strategy in the management of 
PTSD and especially PTSD-related syndromes and comorbidities. Rigorous pre-clinical and 
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Introduction 
The specific aim of this article is to review the available literature on a potentially beneficiary 
role of an adjuvant melatonergic treatment in PTSD, through restoring sleep and circadian 
alignment at different pathophysiological and molecular levels. For this scope, common 
neurobiological underpinnings of PTSD and circadian misalignment are outlined and human 
and animal research findings on melatonergic effects on different levels of the common 
pathophysiology are presented as a narrative review, providing an overview on the most 
important and clinically relevant publications.  
 
The human circadian system and melatonin  
The human circadian system (CS) creates and maintains cellular and systemic rhythmicity, 
through temporal organization and coordination of many physiological and transcriptional 
processes in the organism [1, 2]. The human central CS includes the intrinsically 
photosensitive retinal ganglion cells (ipRGC), the retinohypothalamic tract, the 
suprachiasmatic nucleus (SCN), the superior cervical ganglia and the pineal gland (PGL) [2, 
3]. The SCN is the primary pacemaker of the central CS, coordinating sleep and other 
physiological functions such as immune and autonomic activity, metabolism, neuroendocrine 
hormone secretion and thermoregulation via neuronal and humoral signals [1, 2, 4, 5]. Sleep 
homeostasis acts synergistically and bidirectionally with the central circadian system, but 
also independently restorative towards optimization of the internal temporal order [6]. 
Thereby, sleep onset and sleep stage timing are in particular associated with circadian gene 
expression in the SCN and thus tightly ruled by the CS [7]. Additionally, a peripheral 
oscillating network of partly independent orthologs and paralogs of the core CS components 
(peripheral Zeitgebers) orchestrates biological functions from the level of genetic variance 
and ubiquitously circadian gene expression to peripheral circadian oscillations [8-10]. The 
high complexity of this multi-oscillator system and the high number of external and internal 
rhythmicity-modulating factors enables numerous possibilities for interactions with different 
tissue-specific importance [10]. 
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The major effector of the central CS is the PGL and its neurohormone melatonin [11]. 
Melatonin displays robust and predictable secretion rhythms, that synchronize numerous 
physiological processes in photoperiodic species [12, 13]. The time course of melatonin 
secretion from the pineal gland is strictly adapted to the circadian rhythm and controlled by 
the SCN through GABA-ergic inhibition reactive to a restricted bandwidth of visible light (460-
480 nm, i.e. blue light) [12, 14]. Short-wavelength visible light in the blue-appearing portion of 
the spectrum is most potent for melatonin regulation than other action monochromatic light 
spectra [15]. The major route of melatonin delivery is the direct release into the cerebrospinal 
fluid (CSF) of the third ventricle assisted by a number of epithalamic structures (e.g., 
interpinealocyte canaliculi,  evaginations of the posterodorsal third ventricle) [16]. Melatonin 
concentration reaches high levels at night and low levels during the day, with peak plasma 
levels between 0200 h and 0400 h, thus coinciding with decreases in core body temperature, 
alertness and performance [12, 13]. Melatonin exerts many peripheral physiological actions 
on cell-specific control by binding to the G-protein-coupled melatonin membrane receptors 
MT1 and MT2. Furthermore, melatonin may interact with cytoplasmic factors (i.e. quinone-
reductase-II/MT3 receptors, calmodulin) and nuclear receptors (i.e. retinoid acid receptor 
related orphan and Z receptors (ROR, RZR). Via these interactions, melatonin modulates 
peripheral oscillators and connected secondary molecular pathways, while numerous other 
actions of melatonin are receptor independent (e.g., radical scavenging – see also below) 
[10, 17-21] (cf. Figure 1). The sharp elevation of nocturnal CSF melatonin levels could also 
have substantial protective utility and be responsible for the sleep-specific tissue recovery 
after the daily free radical brain damage due to high oxygen utilization [16]. CSF melatonin 
protects the whole brain as it circulates through the aqueduct into the subarachnoid space 
surrounding the brain and penetrating into the deepest portions of the neural tissue where it 
diffuses into the neural parenchyma [16]. 
On the other hand, melatonin directly influences, in turn, SCN activity and central 
circadian “clock” mechanisms. Thereby, melatonin acts as a modulator of the electrical 
activity in SCN neurons through MT1/MT2 [22, 23]. In addition, melatonin interacts with the 
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“clock” gene (Per1, Per2, Cry1, Cry2, clock, Bmal1, etc.) proteasome transcription loops in 
the SCN, thus modulating circadian rhythms and adjustment to environmental photoperiod 
changes [24]. These extremely multifaceted chronobiotic regulatory actions (see also below) 
have led to the recognition of melatonin as the most important natural substance modulating 
sleep and circadian rhythm [11-13, 17] and as one of the most pleiotropic biological signals in 
photoperiodic species [17, 25]. 
 
=========================== 
Please insert Figure 1 about here 
=========================== 
 
Chronodisruption and stress  
This integrative system of complicated circadian hierarchy enables the interaction of 
circadian, hormonal, and metabolic systems towards an optimal homeodynamic state, 
physical health and environmental adaptation. In the last years, accumulating evidence 
outlines the importance of the human CS, melatonin and circadian-related factors in the 
maintenance of health. A critical loss of this time order at different organizational levels is 
defined as chronodisruption and introduces a breakdown of harmonious functioning internal 
biological systems and appropriate biobehavioral adaptation to external stimuli [26] with short 
and long-term molecular, pathophysiological and epigenetic impact [27]. Dysfunction of 
endogenous clocks, melatonin secretion and melatonergic signalling could, for example, 
contribute to altered gene expression and herewith to numerous physical and mental 
disorders [10]. 
Apart from inadequate exposure to the light-dark cycle (i.e. reduced exposure to 
sunlight during day, increased light exposure at night, natural light isolation), further both 
external and internal factors may also lead to a gradual shift or a total desynchronization of 
the CS. For example, acute and chronic physical, psychological, inflammatory and metabolic 
stress can affect the CS [28-32]. On the other hand, chronic circadian disruption may 
gradually change the fundamental properties of brain systems regulating neuroendocrine, 
immune and autonomic stress systems, similar to chronic stress [4]. Chronodisruption may, 
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thus, sensitize individuals to stress and increase vulnerability for stress-related disorders [33, 
34].  
Chronodisruption in posttraumatic stress disorder 
Posttraumatic stress disorder (PTSD) in DSM-V is classified as a trauma- and stress-related 
disorder with distinctive symptoms following a psychologically distressing event outside the 
range of usual human experience [35]. The estimated lifetime prevalence of PTSD in the 
general U.S. population lies between 5-6% in men and 10-14% in women [36]. Diagnostic 
criteria include current symptoms from each of four symptom clusters: intrusion, avoidance, 
negative alterations in cognitions and mood and alterations in arousal and reactivity including 
sleep disturbances. Sleep disturbances, especially, are prominent clinical features of PTSD, 
while there is evidence that sleep disruption after trauma may represent a core, rather than a 
secondary feature of PTSD and, thus, mediate the neurobiological correlates of the disorder 
through impaired homeostatic balance [37-40]. PTSD is characterized by a vast number of 
symptoms, co-morbid medical conditions and biological findings, also related to sleep 
deprivation (SD) and circadian disruption, suggesting that chronodisruption may represent a 
potential common underlying neurobiological link. Recent articles have focused on the role of 
chronodisruption in the pathophysiology of PTSD, suggesting that sleep and circadian 
dysregulation play a causal pathophysiological role in PTSD development [39-41] (cf. Figure 
2). For example, disrupted melatonin levels in the first 48h after traumatic stress exposure 
were shown to be associated with a higher risk of PTSD development [42].  
In this context, sleep and circadian regulation through exogenous circadian 
entrainment (e.g. melatonergic treatment) could play a central role in the prevention and 
treatment of PTSD. Nevertheless, relevant clinical literature is relatively sparse and mostly 
indirect. To date, the evidence-based recommendation for the first-line pharmacological 
treatment of PTSD includes only selective serotonin reuptake inhibitors (SSRI) and 
serotonin-norepinephrine reuptake inhibitors (SNRI) [43]. 
========================= 
Please insert Figure 2 about here 
========================= 




Melatonergic effects on PTSD-specific pathophysiological states and symptoms 
Sleep 
Stress is known to influence sleep physiology and dream patterns. Acute and chronic stress 
exposure may cause both immediate and long-lasting sleep disruption [38, 44, 45] which 
may, in turn, enhance maladaptive stress regulation [46]. Sleep disturbances are prominent 
clinical features of PTSD [37, 39], often resistant to first-line treatments [47-49] and closely 
related to higher PTSD psychopathology [50, 51], while their effective treatment is associated 
with significant improvement of overall PTSD psychopathology [52-54]. Sleep disturbances in 
PTSD are associated with sleep-related arousal regulation and other functions (i.e. 
dreaming, memory consolidation) [55] and include hyperarousal states, sleep avoidance and 
insomnia, nightmares, sleep terrors and nocturnal anxiety attacks, body-movement and 
breathing-related sleep disorders [37, 40, 56-58]. Most polysomnographic studies 
demonstrated heightened sympathovagal tone during rapid-eye-movement (REM) sleep 
using heart rate variability measures, as well as particularly fragmented REM sleep pattern 
and reduced REM theta activity in early-stage and sustained PTSD [39, 46, 55, 57-61]. On 
the other hand, REM sleep disruption in the immediate aftermath of a trauma has been 
associated with increased REM-related sympathetic activation, representing a major 
moderating and predictive factor in the development of PTSD [40, 62, 63]. Interestingly, there 
is also evidence that sleep impairment prior to traumatic stress exposure could contribute to 
PTSD vulnerability and development [64, 65]. These two studies both showed that reporting 
sleep complaints at baseline resulted in a 2.5-fold increased risk of fulfilling PTSD criteria 3 
months after a trauma in general population admitted to a hospital or after deployment in 
active military troops respectively. 
Sleep propensity and sleep rhythm regulation are temporally related to the SCN-
controlled nocturnal rise in melatonin, which, in turn, exerts its hypnagogic and entraining 
action through MT1 and MT2 receptors of the SCN [23, 66, 67]. The different sleep stages are 
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also strongly circadian-bound and modulated by melatonin [68-70], thus suggesting that 
melatonergic effects may be beneficial for ameliorating sleep disruption and related 
disturbances. Numerous randomized-controlled trials (RCTs) and meta-analytic studies have 
repeatedly confirmed efficacy of exogenous melatonergic treatment. Melatonin and 
melatonergic agonists, when time-appropriately administered, are associated with 
significantly reduced sleep onset latency and increased sleep propensity, efficiency, quality 
and total sleep duration in patients with SD, such as insomnia [23, 67, 68, 71-75]. In addition, 
melatonergic treatment has been shown to lead to i) increased REM sleep percentage and 
continuity, normalization of sleep patterns and improvements in subjective measures of 
daytime dysfunction in neuropsychiatric patients with reduced REM sleep percentage or 
altered sleep patterns, ii) increased REM sleep percentage, advanced sleep/wake rhythm 
phase adjustment and sleep and wake-up propensity in healthy adults, as well as to iii) 
partial prevention of experimentally-induced REM suppression with pindolol in rats [67, 68, 
70, 76]. Melatonergic treatment also shows a benign side-effect profile and safety in the 
short- and long-term administration, with no wearing-off in efficacy and without any 
withdrawal effects or dependence risk [23, 71, 74, 75, 77]. In addition, it has been proven 
also effective in the treatment of primary insomnia, circadian rhythm-related sleep-wake 
disorders, REM sleep behaviour disorders, body-movement and breathing-related sleep 
disorders, as well as in sleep disturbances within the scope of various psychiatric disorders 
(e.g., schizophrenia, depression) [72, 75, 76, 78-81]. Thus, melatonergic treatment could be 
an appropriate alternative for handling PTSD-specific sleep-related symptoms, while its 
implementation could even find use in PTSD prevention. 
 
Circadian gene expression 
Molecularly, the biological clock is based on the transcriptional/translational feedback loop of 
clock genes, not limited to the SCN, but depending on its neuroendocrine/neuronal output 
[82]. Animal research provides evidence that circadian-related genes play a role in the 
neurobiological response to stress, while chronodisruption can lead to alterations in the 
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physiological oscillations of circadian-related gene expression in humans [83-86]. Animal 
research on PTSD and chronic mild stress models provides evidence that stress disrupts the 
regulated gene expression of circadian-related genes (e.g., Per 1, Per 2, Clock, Cry 1, Bmal 
1, Npas 2) in several tissues including the hippocampus and the SCN [87-89]. Recently, a 
genome-wide association study showed that the retinoid-related orphan receptor alpha 
(RORA) gene, a clock gene, may represent a risk gene for PTSD [90].  
Melatonergic regulation is known to adjust and reset amplitude and phase of CNS 
(e.g., SCN, hippocampus, pituitary pars tuberalis) and peripheral (e.g., adrenal gland) 
circadian-related gene transcriptional oscillation independently of previous phase [91-95]. In 
addition, immediate melatonergic treatment directly after exposure to predator scent stress, 
normalized the altered expression of Per 1 and Per 2 genes in hippocampal regions of rats, 
thus suggesting a possible immediate protective effect [88]. In addition, animal studies 
demonstrate a melatonergic regulation of peripheral clock genes oscillation in the adrenal 
gland and their responses to ACTH [91, 92, 96-98]. Melatonin is especially considered to 
play a partially moderating role in the circadian regulation of GR function (e.g. acetylation of 
GR, GR transcriptional activity, GC sensitivity, cell proliferation, etc.) [99-103], which is 
crucially involved in PTSD pathophysiology (see below). 
 
Hypothalamic-pituitary-adrenal-axis and glucocorticoid signaling 
Hypothalamic-pituitary-adrenal (HPA) axis activity is closely linked to the CS and 
characterized by circadian rhythmicity [99, 104-106]. Through various pathways, the SCN 
and melatonin synchronize hypothalamic neuroendocrine neurons, influence adrenal 
sensitivity to adrenocorticotropic hormone (ACTH), stimulate circadian glucocorticoid (GC) 
hormone secretion and interact with the own peripheral rhythm of the adrenal gland [99, 102, 
107, 108]. Furthermore, cortisol and corticotropin-releasing hormone (CRH) are suggested to 
directly modulate PGL activity [29, 109, 110]. Interestingly, the phase angle between cortisol 
and melatonin onset has been identified as a potential useful biomarker in human stress-
related research for distinguishing between healthy and depressed individuals [111]. 
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Neuroendocrine findings in PTSD reveal increased central CRH levels, altered HPA axis 
reactivity with enhanced negative feedback inhibition and blunted circadian cortisol rhythm 
and cortisol awakening response (CAR), while some studies - but not all - have shown 
decreased circulating concentrations of cortisol [112-121]. An enhanced HPA axis negative-
feedback sensitivity in PTSD is in line with an increased GC sensitivity and altered GC 
receptor (GR) responsiveness and density in different cell types in these patients [122-126]. 
Similar changes in HPA axis activity (e.g. reduced ACTH levels, increased CRH levels, 
increased/decreased cortisol levels) with altered endocrine reactivity to stressors (e.g., 
attenuated pituitary ACTH response, increased adrenocortical ACTH sensitivity) and blunted 
circadian cortisol rhythm and CAR have been also reported in patients with chronic insomnia, 
as well as in human and animal SD studies [33, 127-132], while pharmacological GR-
antagonism has been found associated with insomnia symptoms improvement [133]. These 
similarities suggest that the HPA axis- and GC-signaling-specific alterations in PTSD may be 
partially mediated by sleep and circadian disruption [39, 134, 135]. 
Melatonin has been also shown to directly inhibit the adrenocorticotropin-stimulated 
cortisol production in the primate and human adrenal gland [97, 98]. In animal studies, 
chronic exogenous melatonergic treatment counteracts synthetic GC-induced dysregulation 
of the HPA axis. Melatonin has been shown to decrease hypothalamic CRH levels, to 
prevent the chronic stress-induced ACTH decline and to attenuate the adrenocortical 
secretory response in acute and chronic stress models [136-139]. 
 
Sympathoadrenal and autonomic nervous system 
The physiological fluctuations in circadian autonomic activity seen in humans are mainly 
modulated by the CS rhythms, through projections to pre-autonomic hypothalamic neurons 
responsible for cardiovascular autonomic control [140-142]. Chronodisruption is associated 
with increased sympathoadrenal activity and blunted autonomic and cardiovascular 
rhythmicity and responsiveness, constituting a major cardiovascular risk factor [33, 143]. 
PTSD patients exhibit similar autonomic findings such as hyperarousal, exaggerated startle 
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responses, increased basal heart rate and sympathovagal balance during day and night, 
increased autonomic responses to traumatic stimuli and norepinephrine levels, blunted 
autonomic diurnal rhythmicity and salivary alpha-amylase awakening response and overall 
reduced heart rate variability [63, 120, 144-150]. These findings suggest that 
chronodisruption-related chronic neuroautonomic dysregulation, could be responsible for the 
higher cardiovascular risk seen in this disorder. In particular, PTSD has been repeatedly 
associated with hypertension, cardiovascular diseases and myocardial infarctions and is 
increasingly considered an established risk factor for cardiovascular disease [151-156].  
 Melatonin has gradually gained interest as a potential cardioprotective and 
antihypertensive agent [157-159]. Apart from its antioxidant and scavenger properties 
reviewed below and its hypotensive effect, melatonin has been shown to centrally modulate 
autonomic nervous system (ANS) activity by inhibiting central sympatho-adreno-medullary 
(SAM) outflow and shifting autonomic balance in favour of vagal activity [141, 160-163]. In 
human and animal research, melatonin is shown to entrain disrupted autonomic rhythmicity 
and augment sympathoadrenal rhythm amplitude, reduce heart rate, norepinephrine levels, 
arousal and startle responsiveness, attenuate both orthostatic baroreflex and mental-stress-
related sympathetic response and increase overall heart rate variability [140, 164-169]. As it 
is known that sympathetic activation of the paraventricular nucleus of the hypothalamus 
(PVN) inhibits melatonin secretion [5], restoring the autonomic imbalance seen is PTSD may 
also have reciprocal beneficial effects on the physiological melatonin secretion rhythm and 
as such further contribute to a reduction in PTSD symptoms. 
 
Neuroimmunomodulation 
The CS and immune system are bi-directionally connected through intricate interactions 
between the autonomic nervous system and GC hormones influencing the expression of 
circadian genes and cytokine signaling [29, 170-176]. Immune system reactivity follows 
circadian rhythms imposed by the SCN and sleep synchronisation, whereas chronodisruption 
is associated with altered immune function, disarranged immunity-related activity rhythms 
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and inflammation [170, 177-180]. Chronic stress with impaired GC hormone signaling and 
chronic dysregulation of the HPA axis and SAM system also enhances chronic inflammation, 
immunosuppression and immunosenescence and could herewith contribute to accelerated 
biological aging and stress-related pathology of inflammatory-related medical conditions 
[113, 181-183]. Growing evidence concordantly associates PTSD with peripheral immune 
dysregulation and low-grade inflammatory excess state (higher IL-6, IL-1b, C-RP, TNF-α and 
lower IFN-γ and IL-4 levels, lower lymphocyte counts, altered mononuclear and natural killer 
(NK) cell activity, etc.) [184-193], possibly involved in the overall increased morbidity rates 
seen in this disorder [194, 195]. Interestingly, low-grade inflammation even prior traumatic 
exposure has been also found to be a possible predisposing factor towards PTSD 
development [196]. 
Melatonin plays a fundamental role in the reciprocal relationship between the 
neuroendocrine and immune system [29, 170, 172, 173, 175, 176, 197-202]. Melatonin acts 
as an pluripotent immune regulator, immune-stimulating under basal or immunosuppressive 
conditions and immune-inhibiting in exacerbated immune responses [203]. It possesses 
numerous direct and indirect, as well as acute and chronic cellular and humoral 
immunomodulatory, antioxidative and anti-inflammatory properties both in vitro and in vivo 
[172, 200, 204-211]. Melatonin demonstrates endocrine, paracrine and autocrine effects in 
the leukocyte compartment, through modulation of pro-inflammatory enzymes, production of 
inflammatory mediators (i.e. cytokines, leukotrienes) and apoptotic processes [200, 211]. 
Melatonin also exerts important effects in cells of innate immunity [199]. Specifically, 
melatonin stimulates the production of granulocyte/macrophage progenitor cells, NK cells, 
CD4+ cells and various cytokines from NK cells and T-lymphocytes, while limits cell 
migration [202, 212]. In addition, animal models suggest that melatonin counteracts negative 
immune effects of acute stress [213]. For example, in animal models, melatonin inhibits the 
endotoxin-induced increase in serum TNF-α levels, improves humoral and cell-mediated 
immune responses in GC-induced immunosuppression and restores metabolic-stress-
induced elevated IL-1β, IL-6, TNF-α, IFN-γ and CRP and reduced IL-4 and IL-10 levels [214-
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217]. These properties suggest a central pleiotropic role of melatonin in physiological 
immune processes and immunosenescence and have placed melatonin among the newest 
promising agents in immunotherapy [211]. Of particular interest for cancer immunotherapy is 
the observation that melatonin causes synergistic effects with specific cytokines, which may 
lead to higher antitumoral activity and a lower incidence of side effects [204]. 
 
Metabolism 
The CS is closely connected with the regulating expression and activity of key players in 
cellular metabolism [143, 218]. Chronodisruption can lead to pro-orexic lipid and glucose 
metabolic alterations and consequently to related pathological metabolic conditions (e.g., 
diabetes, obesity, metabolic syndrome) [219-221]. PTSD and PTSD-related endocrine 
findings have been repeatedly associated with higher rates of metabolic clinical 
manifestations such as higher BMI and obesity, higher leptin and insulin levels with lower 
insulin sensitivity, and higher risk for metabolic syndrome, type-2 diabetes and dyslipidemia 
(higher total cholesterol, triglycerides, low-density lipoprotein-cholesterol and lower high-
density lipoprotein-cholesterol) [222-228]. 
Melatonin is a major metabolic regulator and responsible for an adequate energy 
balance and mobilization [229]. Among other functions, melatonin regulates glucose 
homeostasis and proper synthesis, secretion, and action of insulin, plasma lipid profile, 
activation of brown adipose tissue, and the browning process of white adipose tissue. [230-
232]. In experimental animal models, M melatonin LT reduces both adiposity and body 
weight, inhibits insulin release, increases insulin sensitivity and ameliorates the altered 
biochemical metabolic alterations seen in animals fed on a high-fat diet (e.g., dyslipidemia, 
oxidative stress) [216, 233, 234]. Similarly, in clinical human research, melatonin treatment 
has been proven beneficial in patients with metabolic syndrome, diabetes and peri-
/postmenopausal women resulting in normalization of lipid profiles and reduced HbA1c levels 
[235-237]. Melatonin seems also efficacious in the prevention of drug-related metabolic side-
Agorastos & Linthorst: Melatonin in PTSD   14 
 
effects (e.g., weight gain, abdominal obesity, hypertriglyceridemia), as for example observed 
in patients treated with olanzapine [238]. 
 
 
Oxidative stress and traumatic brain injury  
Oxidative stress (OXS), defined as a disequilibrium between oxidant generation and 
antioxidant response, represents cellular chemical stress by an excess of free radicals (e.g., 
reactive oxygen species, ROS and reactive nitrogen species, RNS). OXS can be triggered by 
many exogenous (e.g., toxins, chemicals, UV-light, smoking) and endogenous (e.g., 
hyperglycemia, dyslipidemia, cytokines, chemokines) factors and deplete cellular defences, 
thus initiating inflammation [239, 240]. Free radicals from subcellular compartments lead to 
severe structural injuries and functional alterations of macromolecules, membranes, cellular 
organelles, as well as coding material (i.e. through lipid peroxidation or protein oxidation) [21, 
239]. For example, telomere length decline, as a proxy for cellular aging, has been 
associated with OXS [241, 242].  
OXS plays a major pathophysiological role in the development of many disorders, 
potentially including psychiatric and neurodegenerative conditions [239, 241]. The effects of 
early-life and traumatic stress on higher CNS and peripheral OXS-related marker levels have 
been investigated in animal models, but also clinical research. For example, early-life stress 
and PTSD have both been linked to shorter telomere length (a novel biomarker of 
accelerated cell aging and OXS) in clinical research [241, 243-245]. Respectively, higher 
levels of glutathione (a marker for neuronal OXS) were reported in dorsolateral prefrontal 
cortex and anterior cingulate cortex of PTSD patients using proton magnetic resonance 
spectroscopy [246]. These findings are supported by several animal PTSD-models reporting 
increased OXS markers and OXS-related metabolomic and transcriptomic effects in blood, 
adrenal gland, liver and CNS tissues compared to controls [246-248]. This line of evidence 
suggests that trauma-related stress, as seen in PTSD, potentiates OXS, thus modulating 
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neural integrity, accelerating cellular aging and increasing neuropsychiatric vulnerability [240, 
249]. 
The is a large amount of data suggesting that melatonin exhibits distinct antioxidant 
characteristics and free radical scavenging properties, which has been also hypothesized to 
be the evolutional initial and primary function of melatonin [20, 250]. Given its small 
molecular size and its amphipathic behaviour, melatonin efficiently protects every subcellular 
compartment against OXS through a variety of mechanisms [21]. Melatonin and its 
metabolites exert direct scavenging effects on ROS/RNS and radical products, reduce free 
radical formation by support of mitochondrial electron flux, induce redox and other 
antioxidant enzymes while suppressing pro-oxidant enzymes, contribute to the maintenance 
of membrane stability, protect mitochondrial DNA and homeostasis, reduce metal-induced 
toxicity through concurrent chelating cascades and finally induce defence mechanisms 
suppressing inflammation [20, 21, 211, 239, 242, 250-258]. Especially in stress-related 
research, animal models have shown that melatonin can effectively counteract OXS and 
neurodegeneration, suppress various apoptotic markers and ameliorate the oxidant effects of 
GCs induced by stressful conditions [259-262].  
These facts appear even more important, when considering the correlation between 
traumatic brain injury (TBI) and PTSD. The pathogenesis of TBI is directly related to 
secondary biochemical cascades following injury and exacerbating primary damage, which 
result in the imbalance between oxidant agents and antioxidant defence and, thus, lead to 
OXS, excitotoxicity, ionic imbalances, cerebral edema, neuroinflammation, neural 
dysfunction and cell loss with functional impairment [263-265]. Both PTSD and TBI 
commonly occur in the general population but are especially comorbid in military populations 
[266, 267]. TBI shares overlapping pathophysiological pathways with PTSD (i.e., altered 
brain networks with reduced prefrontal function, volume loss in amygdala, etc.), leading to 
similar symptoms (e.g., cognitive impairment, sleep disruption) [268, 269] higher levels of 
PTSD symptomology [267, 270-272] and increased vulnerability to the disorder [270, 273-
275]. Prospective studies have confirmed TBI as a major predictor of PTSD risk [276]. In 
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animal models of TBI, but also in human RCTs, melatonin has proven beneficial in 
preventing and ameliorating the effects of the neurotrauma, such as OXS, brain edema, and 
neuronal degeneration, as well as TBI-related functional impairment through its antioxidant, 
neuroprotective and antiapoptotic qualities [277-282]. Interestingly, TBI in rats has been 
found to cause increased DNA methylation and reduced expression of the Aanat gene [283], 
encoding serotonin N-acetyltransferase, one of the two enzymes involved in the synthesis of 
melatonin from serotonin. 
Cognitive function, memory and neurocircuitry 
Both animal and human studies demonstrate cognitive performance being sensitive to the 
CS [284-286]. Cognitive performance as well as memory processing, formation and 
consolidation are directly influenced by the circadian clock, melatonin and the HPA axis [284-
294]. Sleep promotes memory consolidation, particularly for emotionally salient information 
[285], while SD may reduce the connectivity between amygdala and PFC [295] and disrupt 
memory consolidation [296-300]. Accordingly, several studies have successfully replicated 
distinctive neuropsychological deficits (e.g. deficits in attention, learning & memory, executive 
function, decision making) in association to sleep disruption in humans [301-305].  
Besides sleep disruption, acute and traumatic stress also affect neural correlates of 
memory formation [306-308]. PTSD is similarly associated with several cognitive deficits, 
crucial for the development and maintenance of the disorder [309-311] and in part directly 
related to sleep disturbances [312]. Specifically, impaired executive functioning, learning, 
cognitive information processing, free and cued recall, recognition and declarative memory 
performance, verbal memory, fear conditioning, fear extinction and explicit memory for 
emotional material have been repeatedly reported in patients with PTSD [311, 313-316]. 
Neuroimaging studies have reported hyporesponsive medial PFC regions, hyper-responsive 
amygdala and smaller hippocampal volume with decreased activation in patients with PTSD 
[310, 317-319]. These alterations are related to the impaired associations between 
contextual stimuli and aversive events, prediction errors during fear learning and extinction, 
disarranged regulation of negative emotion and fear gating by contextual information 
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reported in this disorder [320-323]. In addition, animal studies have put forth a significant 
impact of circadian rhythmicity on homeostasis, neurogenesis and neural activation in these 
exact brain regions [324-329]. 
Interestingly, research findings suggest a direct enhancing effect of melatonergic 
transmission in stimulus processing and memory consolidation, especially under stress [330-
332]. In addition, in animal models melatonin has been associated with positive structural 
effects on synaptic plasticity and dendritic remodeling in cortical and hippocampal brain 
areas associated with cognitive and memory function, which may be caused by alterations in 
the regulation of cell adhesion molecules expression [93, 333]. Melatonin has also been 
shown to influence circadian clock gene expression in hippocampal neurons (see above) and 
to protect these neurons from oxidative stress, by preventing GC-related toxicity and 
inhibition of hippocampal neurogenesis and cell proliferation through decrease of receptor 
translocation to nuclei in models of SD and chronic stress [260, 334-336].  
Melatonergic action has been shown to resemble sleep effects and prevent and/or 
reverse stress-, SD- and aging-related cognitive impairment and memory deterioration [334, 
335, 337-340], as well as facilitate conditional cued fear extinction [341], without leading to 
next-day cognitive impairment, as seen with other hypnotics [342]. Reports suggest, that 
interventions aimed at restoring normal hippocampal function, disrupting dysfunctional 
aversive memories and enhancing extinction of conditional cued fear may serve future 
treatment strategies for PTSD [320, 341, 343].  
 
Pain 
Chronic pain syndromes and hyperalgesia to nociceptive stimuli are often reported in PTSD 
and are also associated with trauma history without PTSD [344-347]. Chronic pain is also 
considered a form of chronic stress and has been associated with hypocortisolism and 
enchanced HPA axis negative-feedback sensitivity, similar to PTSD [348-354]. Pain 
modulation and nociception exerts circadian variations [355-357] and interacts bidirectionally 
with sleep and the CS, with SD leading to hyperalgic states and acute or chronic pain to 
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sleep and chronodisruption [358-363]. In particular, pain modulation seems closely linked to 
melatonin, which acts direct or indirect through MT1, MT2, µ-opioid, GABAB and NMDA 
receptors at spinal and supraspinal levels [364-368]. The analgetic effect of melatonin is 
supported by both experimental and clinical evidence. Animal research has confirmed dose-
dependent, antinociceptive and analgetic effects of melatonin in acute, chronic and 
inflammatory pain models [369-371]. In clinical human research, endogenous melatonin 
secretion has been shown to be responsive to acute pain episodes [372], while exogenous M 
melatonin LT has shown analgesic, antihyperalgesic and antiallodynic efficacy in intra- and 
postoperative analgesia [373] and experimental pain studies [374], as well as in some, but 
not all studies of chronic pain syndromes (e.g., fibromyalgia, irritable bowel syndrome, 
endometriosis, migraine, neuropathic pain) [366, 369, 375-378]. Melatonergic treatment 
could, thus, represent a novel efficacious alternative treatment in patients with chronic pain 
comorbidity, such as PTSD patients [366, 367, 369, 379]. 
 
Epigenetics 
Epigenetic regulatory mechanisms at the chromatin, such as DNA (de-)methylation and 
histone modifications, act in concert bridging environmental and internal signals to modulate 
gene expression, thus resulting in transient as well as sustained transcriptional changes. 
Epigenetic modifications, as molecular consequences of stress and trauma experience, 
could play an important role in the aetiology of stress-related mental disorders and together 
with individual genetic predisposition explain disease susceptibility and stress resilience 
[380-383]. Early life events and childhood trauma are repeatedly shown to be associated with 
epigenetic changes and altered gene expression profiles especially in the CNS (e.g., 
hippocampus, amygdala), which influence stress responses and memory consolidation [382, 
384-386]. For example, fear conditioning rodent models support the role of epigenetic 
regulation e.g. through stabilization of context- and cue-triggered fear conditioning [387, 388]. 
Moreover, subjecting rats to a an acute psychological stressful challenge has been shown to 
cause behavioral adaptations, which result from interactions between GR and the ERK1/2-
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MSK1-Elk-1 signaling pathway leading to specific histone modifications in promoters of 
immediate early genes such as c-Fos and Egr-1 [389].  
There is an increasing body of evidence in humans for gene programming and 
epigenetic regulation of specific genes in the pathophysiology of PTSD [388, 390-392]. 
Although there are no direct prospective findings on PTSD-specific epigenetic modifications, 
recent observations on the role of stress-related gene expression, early developmental 
influences and transgenerational effects are compatible with epigenetic explanations [393]. In 
particular, some GC-signaling related genes (e.g., GCR gene promoter 1F) are subject to 
stress- and trauma-related epigenetic regulation throughout life and may be useful as 
biomarkers associated with development, prognosis and symptom state of PTSD [394, 395].  
The circadian machinery is highly involved in such epigenetic regulatory mechanisms, 
promoting specificity and seasonal/circadian plasticity of molecular environmental responses 
[396-398]. Epigenetic regulation utilizes to some extent highly sophisticated circadian 
transcriptional-translational feedback loops that modulate expression of cellular transcripts, 
while the circadian epigenome shares intimate links with chromatin remodelling (e.g., 
CLOCK protein has intrinsic histone acetyl transferase activity) [399].  
Thereby, melatonin is particularly involved, modulating epigenetic processes in a 
circadian manner together with other epigenetic factors [239, 400-402]. Most importantly, 
melatonin is also suggested to exert direct beneficial effects in epigenetic regulation and 
protect from or even restore stress-related epigenetic changes [239, 401, 403-405]. In vitro, 
melatonin can regulate epigenetic modifications by both DNA methylation and histone 
modifications through its effects on nuclear receptors, co-regulators, histone acetylating 
enzymes and free radical scavenging [406-408]. Melatonin thus exerts prophylactic effects 
on the epigenome by decreasing gene-silencing related mRNA expression, inhibiting 
telomerase activity and significantly increasing chromatin remodeling (i.e. histone 
deacetylase isoforms, histone H3 acetylation activity) and gene transcription [406, 409]. 
 
Mood and anxiety   
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Depression and anxiety disorders are highly comorbid psychiatric conditions in PTSD 
patients, which may share common risk factors and pathophysiological background [410, 
411]. Most human research findings focus on the role of CS in depression, proposing that SD 
and chronodisruption are under-recognized but vital underlying mechanisms contributing to 
the development of mood disorders [412-415]. Several studies suggest, for example, an 
important role of circadian gene expression and polymorphisms in modulating reward 
motivation and active behaviour and, thus, determining mood disorders’ susceptibility, 
recurrence and treatment response [413, 414, 416, 417]. A plethora of findings has also 
reported significant and acute negative effects on positive mood correlates in the aftermath 
of SD conditions in healthy people [418, 419]. Interestingly, studies in rats have shown that 
SD impacts on hippocampal serotonin and free GC hormone levels [420]. With respect to 
anxiety and anxiety disorders, evidence from human research has primarily focused on the 
relation between these conditions and SD [421, 422], while only relatively few studies 
examined circadian gene-related effects on anxiety-related behaviour [423, 424]. 
Although interventions able to resynchronize the human circadian system (i.e. SD, 
light therapy, etc.) have shown some potential in the treatment of depression [425, 426], 
there are no data unquestionably supporting the antidepressant efficacy of melatonin and 
melatonin receptor agonists [75, 427, 428], with the exception of agomelatine - a MT1/MT2 
agonist and 5-HT2C antagonist with antidepressant and anxiolytic potency [72, 429-432]. On 
the other hand, there is some evidence for (mostly acute) anxiolytic effects of melatonin and 
melatonin receptor agonists [431, 433]. Nevertheless, besides one single case-report on 
agomelatine treatment in PTSD, there is no clinical evidence for melatonin and melatonin 
receptor agonist effects in PTSD. 
 
Further Co-morbidities 
Traumatic experience and PTSD are frequently related to several specific co-morbidities, 
such as chronic fatigue syndrome (CFS) [434-437], fibromyalgia [438-442], rheumatoid 
arthritis [443]. These syndromes share a very similar underlying neuroendocrinological profile 
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to PTSD (e.g., hypocortisolism, blunted diurnal cortisol rhythm and HPA axis reactivity) [444-
449] and have all been repeatedly associated with evidence supporting circadian disruption 
[354, 450-459]. Interestingly, there is also relatively well-founded evidence for the efficacy of 
an adjuvant melatonergic treatment in these disorders. Several RCTs and open trials 
reported efficacy of melatonergic treatment with respect to the reduction of pain perception 
and sleep in fibromyalgia, as well as fatigue, concentration, motivation and activity in CFS, 
although there is only a small number of studies in general [377, 379, 460-465].  
Similarly, traumatic stress experience and PTSD have been associated to an overall 
higher risk of cancer incidence, recurrence and mortality, partly in a dose-response manner 
[194, 195, 466-469]. Cancer biology has been intensively linked to the CS and 
chronodisruption [470-472], while melatonin has shown promising qualities as an oncostatic 
and adjuvant cancer treatment as there is evidence that melatonin can promote endocrine 
re-synchronization, tumor growth regression, stability of disease without tumor progression, 
as well as survival in cancer patients [473-477]. Melatonin reduces severe ROS and RNS-
related DNA damage inducing cancer initiation and tumor progression [5, 6], controls tumor 
growth by activating signal transduction pathways, altering the expression of growth and 
differentiation-related genes [409, 478]. Melatonin is shown to upregulate the tumor 
suppressor gene GPC3, inhibit telomerase activity and endothelin-1 synthesis, inhibit COX-2 
and p300 and downregulate cancer-related oncogenes (i.e. breast cancer EGR3 and 
POU4F2/Brn-3b) either by methylation of the Aromatase gene (CYP19) or deacetylation of 
CYP19 histones resulting in chromatin closing and binding inhibition of transcriptional factor 
triggering the expression of oncogenes [404, 409, 478-480]. A recent meta-analysis of RCTs 
confirmed the efficacy and safety of melatonin in cancer treatment [474], suggesting that 
melatonin is influential in inhibiting both cancer initiation and cancer cell growth. 
 
Discussion 
Loss of circadian rhythmicity fundamentally affects the neuroendocrine, immune and 
autonomic system, similar to chronic stress and may play a central role in the development of 
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stress-related disorders. Disruption of sleep and of circadian rhythm after trauma represent 
core rather than secondary features of PTSD [37-40, 62, 63, 481] and are both a 
precipitating and perpetuating factor of the disorder [482-484]. Recent articles have focused 
on the role of the sleep and circadian disruption in the pathophysiology of posttraumatic 
stress disorder (PTSD), suggesting that chronodisruption plays a causal role in PTSD 
development. Circadian disruption could precipitate the neurobiological correlates of the 
disorder through impaired homeostatic balance with neuroendocrine, immune, metabolic and 
autonomic dysregulation, resulting in the extensive symptomatology and co-morbidiy of 
PTSD [41, 151-155, 184, 443, 485-495]. 
Standard sleep pharmacotherapies in PTSD may treat sleep quantity sufficiently, but 
often fail to improve daytime functioning and restore the unique CS-related neurobiological 
changes in PTSD [6, 496]. Thus, the development of pharmacological interventions that 
would counteract changes in PTSD-related neurocircuitry and restore CS-related alterations 
could represent an interesting novel therapeutic strategy [413, 497-499]. Such 
pharmacotherapies could be incorporated into any standard PTSD treatment and be applied 
in addition to psychological-behavioral interventions, in cooperation with sleep specialists 
[61].  
Melatonin is fundamental for circadian regulation and also plays a crucial role in 
several brain processes affected in PTSD. Recent experimental findings emphasize on the 
role of melatonin in mechanisms of sleep, cognition and memory, metabolism, pain, 
neuroimmunomodulation, stress endocrinology and physiology, circadian gene expression, 
oxidative stress and epigenetics. The efficacy of melatonin and melatonergic treatment 
beyond sleep regulation has been considered and investigated in numerous clinical 
conditions also found as comorbidities in PTSD, while most results confirm the very low 
toxicity and side-effects range of melatonin over a wide range of doses [78, 460, 500]. The 
hypnotic, rhythm resynchronizing, antioxidant, anti-inflammatory, antinociceptive, 
neuroprotective, pro-cognitive, metabolic, antiapoptotic and anxiolytic actions of melatonin 
and melatonergic agents could therefore represent a promising adjuvant contribution to the 
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clinical treatment and prevention of stress-related syndromes and comorbidities in mental 
disorders in general and PTSD in particular [10, 41, 499, 501-503] (cf. Figure 3).  
 
========================= 






Understanding the mechanisms susceptible to chronodisruption following trauma exposure 
and their role in a chronically dysregulated circadian network in PTSD could be valuable 
towards enabling innovative preventive strategies and psychochronobiological treatment 
possibilities in PTSD patients and high-risk trauma-exposed populations [8, 39, 58, 104, 
504]. Unfortunately, relevant clinical literature is relatively sparse and regularly neglecting the 
potential effect of CS on the development of the pathophysiological findings in this disorder 
[57, 58, 114, 505]. Adjuvant melatonergic treatment could provide a potentially promising 
treatment strategy with beneficial effects in the treatment of PTSD and especially PTSD-
related syndromes and comorbidities. This theoretical concept deserves thorough further 
investigation through pre-clinical research and clinical confirmation through RCTs assessing 
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Figure 1.  Simplified diagram of pathways modulating melatonin secretion and 
melatonergic effects.   
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Figure Legend:  
SCN: suprachiasmatic nucleus; PVN: paraventricular nucleus; SCG: superior cervical 
ganglion; MT1, MT2: melatonin membrane receptors 1 and 2, MT3: quinone-reductase-II; 
ROR: retinoid orphan nuclear receptors; RZR: retinoid Z nuclear receptors; ROS: reactive 
oxygen species; RNS: reactive nitrogen species; HPA axis: Hypothalamus-pituitary-adrenal 
axis. Modified from [10, 18, 25]. 
Figure 2.  Proposed model of PTSD development: From trauma to sustained 
chronodisruption.  
 




Figure Legend:  
Proposed model of PTSD development. Arrows: temporal order; SAM: sympathoadrenal-
medullary system; ANS: autonomic nervous system; HPA-axis: hypothalamus-pituitary-
adrenal-axis; GC: glucocorticoid. 
Figure 3. Overview of beneficial melatonergic effects on PTSD-related biological 
correlates  




Melatonin exerts preventing and restoring/synchronizing effects with beneficial actions on the 
main PTSD-related biological alterations (red boxes). MLT: melatonin; HPA-axis: 
hypothalamus-pituitary-adrenal-axis; SAM: sympathoadrenal-medullary system; ANS: 
autonomic nervous system; GC: glucocorticoid; CGE: circadian gene expression; TBI: 
traumatic brain injury. 
 
 
